Skip to main content
Hassane Zarour, MD, Dermatology, Pittsburgh, PA

HassaneMohamedZarourMD

Dermatology Pittsburgh, PA

Professor, Medicine and Dermatology, University of Pittsburgh School of Medicine

Dr. Zarour is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Zarour's full profile

Already have an account?

  • Office

    5117 Centre Ave
    Research Pavilion, Suite 1.32a
    Pittsburgh, PA 15213
    Phone+1 412-623-3272

Summary

  • Dr. Hassane Zarour is a Pittsburgh-based dermatologist specializing in dermatology and cutaneous oncology. He completed his education in 1991 at the University of the Mediterranean Faculty of Medicine. His expertise includes skin cancers, melanoma, and the immunotherapy of cancer. Dr. Zarour has several publications, including studies on neoadjuvant therapies, tumor-infiltrating lymphocytes, and melanoma microbiota. He has participated in clinical trials involving advanced melanoma treatments, highlighting his focus on innovative approaches in melanoma management.

Education & Training

  • University of the Mediterranean Faculty of Medicine
    University of the Mediterranean Faculty of MedicineClass of 1991, Dermatology and Cutaneous Oncology

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2003 - 2026

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Combination Therapy Shows Promising Results in Treating Stage 3 Melanoma
    Combination Therapy Shows Promising Results in Treating Stage 3 MelanomaOctober 31st, 2024
  • Fecal Microbiota Transplants May Improve Resistance to Melanoma Immunotherapy
    Fecal Microbiota Transplants May Improve Resistance to Melanoma ImmunotherapyOctober 13th, 2021
  • Fecal Microbiota Transplant Changes Melanoma Immunotherapy Non-Responders to Responders
    Fecal Microbiota Transplant Changes Melanoma Immunotherapy Non-Responders to RespondersFebruary 5th, 2021
  • Join now to see all

Grant Support

  • Reversing Melanoma-Induced T Cell DysfunctionNational Cancer Institute2011–2012
  • Optimization Of Melanoma Vaccines With T-Helper EpitopesNational Cancer Institute2009–2012
  • Melanoma Vaccines With Peptides, Protein And AdjuvantNational Cancer Institute2005–2009
  • Optimization Of Melanoma Vaccine With T Helper EpitopeNational Cancer Institute2002–2007
  • Promune W/Wo Chemo Trtmt Stage III B/C/Iv MelanomaNational Center For Research Resources2005
  • Pilot Immun W/Cpg 7909 Or Multi-Epitope Immunogen Nyeso-1National Center For Research Resources2005